Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
Sign Up to like & getrecommendations! Published in 2022 at "Science Advances"
DOI: 10.1126/sciadv.abo2341
Abstract: Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first randomized trial evaluating a C3 inhibitor, AMY-101, in severe COVID-19… read more here.
Keywords: complement inhibition; severe covid; covid; inhibition severe ... See more keywords